

Catabolism of leukotriene B₅ in humans

Clemens von Schacky,¹ Claus Fahrner, and Sven Fischer

Medizinische Klinik Innenstadt, University of Munich, Munich, FRG

Abstract Human neutrophils, enriched by dietary supplementation with eicosapentaenoic acid, form leukotriene (LT)B₅ in addition to LTB₄ upon stimulation. LTB₅ is one order of magnitude less biologically active than the potent chemokinetic and chemoattractant LTB₄. Catabolites of LTB₅ have not yet been characterized in vitro and ex vivo. It is unknown whether catabolism of LTB₅ interferes with catabolism of LTB₄. This report describes catabolism of LTB₅ to 20-OH-LTB₅, which in turn is catabolized to 20-COOH-LTB₅. The structures of the two catabolites were established by UV-absorbance, behavior on reverse-phase high-performance liquid chromatography, enzymatic analysis of human neutrophils, and gas chromatography-mass spectrometry. In vitro, formation of LTB₄ was delayed and formation of its catabolites was depressed by exogenous eicosapentaenoic acid. By supplementing the diet of six volunteers with 5 g eicosapentaenoic acid/day for 7 days, eicosapentaenoic acid quadrupled in neutrophil phospholipid fatty acids. Consequently, LTB₅, 20-OH-LTB₅, and 20-COOH-LTB₅ were detected ex vivo. In contrast to the findings in vitro, however, levels of LTB₄, 20-OH-LTB₄, and 20-COOH-LTB₄ were unaltered by the dietary intervention. Thus, in vitro, but not ex vivo, addition of eicosapentaenoic acid, and subsequent formation of LTB₅, impeded catabolism of proinflammatory LTB₄. — von Schacky, C., C. Fahrner, and S. Fischer. Catabolism of leukotriene B₅ in humans. *J. Lipid Res.* 1990. 31: 1831-1838.

Supplementary key words eicosapentaenoic acid • n-3 fatty acids • fish oil • eicosanoids

Polymorphonuclear leukocytes isolated from volunteers who ingested eicosapentaenoic acid (EPA) form LTB₅ (1-3). LTB₅ is one order of magnitude less biologically active than LTB₄, the potent neutrophil chemotactic and chemokinetic compound, derived from arachidonic acid (4-9). Binding of LTB₅ to human neutrophil LTB₄ high affinity binding sites is lower than that of LTB₄ (8, 10). In vitro, with exogenous EPA or 12S-hydroxy-EPA, neutrophil formation of LTB₄ can readily be reduced dose dependently (1, 11-13). Thus, arachidonic acid, EPA, and its platelet-derived metabolite 12S-hydroxy-EPA compete for 5-lipoxygenation in stimulated neutrophils. Enrichment of human neutrophils with EPA, by dietary supplementation for at least 3 weeks, reduces their formation of LTB₄ ex vivo (14). By the mechanisms cited, and by suppression of monocyte cytokine formation (15), EPA is thought to mediate the antiinflammatory effects, observed in epidemiologic and some animal studies (14). In dietary in-

tervention studies with fish oils in patients with chronic polyarthritis, asthma, or chronic inflammatory bowel disease, some benefit has been reported after 4-12 weeks of dietary n-3 fatty acid supplementation (14, 16-19).

In human polymorphonuclear neutrophils, LTB₄ is catabolized, and thereby largely inactivated, to 20-OH-LTB₄ by a cytochrome P-450 enzyme system (20-26). Arachidonic acid and a number of lipoxygenase products therefrom are also subject to 20-hydroxylation by cytochrome P-450 enzyme system(s) (26-28). 20-OH-LTB₄ is further catabolized to an even less biologically active 20-COOH-LTB₄ (20, 21, 24) via the aldehyde intermediate 20-CHO-LTB₄ (29). Preliminary evidence for formation of 20-OH-LTB₅ has recently been obtained in vitro (30). Further catabolism of 20-OH-LTB₅ is yet unknown. Qualitative differences between cellular metabolism of EPA in vitro and ex vivo have been described (31, 32). Catabolites of LTB₅, however, have not been demonstrated ex vivo.

LTB₅ seems to inhibit 20-hydroxylation of LTB₄ in a purified enzyme preparation (26). Competition for 20-carboxylation between 20-OH-LTB₄ and a 20-OH-LTB₅, if formed, is likely. These interactions at each catabolic step might very well affect levels of the biologically highly active LTB₄, and remain to be studied. Moreover, catabolism of LTB₄ during ingestion of n-3 fatty acids has not yet been investigated.

Therefore, we studied simultaneous formation and catabolism of LTB₄ and LTB₅ in human neutrophils in vitro and ex vivo. Neither LTB₄ nor LTB₅ has been quantified in this manner in the presence of exogenous or endogenous EPA.

Abbreviations: EPA, eicosapentaenoic acid; leukotriene (LT) B₄, 5S,12R-dihydroxy-6-*cis*-8,10-*trans*-14-*cis*-eicosatetraenoic acid; 20-OH-LTB₄, 5S,12R,20-trihydroxy-6-*cis*-8,10-*trans*-14-*cis*-eicosatetraenoic acid; 20-COOH-LTB₄, 5S,12R-dihydroxy-20-carboxy-6-*cis*-8,10-*trans*-14-*cis*-eicosatetraenoic acid; LTB₅, 5S,12R-dihydroxy-6-*cis*-8,10-*trans*-14,17-*cis*-eicosapentaenoic acid; 20-OH-LTB₅, 5S,12R,20-trihydroxy-6-*cis*-8,10-*trans*-14,17-*cis*-eicosapentaenoic acid; 20-COOH-LTB₅, 5S,12R-dihydroxy-20-carboxy-6-*cis*-8,10-*trans*-14,17-*cis*-eicosapentaenoic acid; HPLC, high performance liquid chromatography; RP-HPLC, reverse-phase HPLC.

¹To whom reprint requests should be addressed at: Medizinische Klinik Innenstadt, University of Munich, Ziemssenstr. 1, D-8000 Munich 2, Federal Republic of Germany.

Neutrophil preparations

After an overnight fast, venous blood was obtained from healthy male volunteers via a free flow technique through a 17-G needle. Neutrophils were prepared as described previously (13, 28, 33). The preparation resulted in platelet-free suspensions, in which 99% were polymorphonuclear neutrophils; 3×10^7 were used for each experiment. Neutrophils were stimulated with the model compound ionophore A23187 (10 μ M) (Sigma, Munich, FRG) or carrier (13, 28, 33).

Experiments with exogenous EPA

In vitro studies. EPA (Sigma, Munich, FRG) was freshly prepared as sodium salt in ethanol (13). Two sets of experiments were carried out four times with blood from different donors: *a*) time course: neutrophils or buffer were incubated for 0, 20, 40, 60, 80, 100, or 120 min in the presence or absence of 15 μ M EPA; *b*) concentration curve: neutrophils or buffer were incubated for 80 min in the presence of 0, 0.6, 1.5, 3.0, 6.0, 15, 30, or 60 μ M EPA.

HPLC analysis. Incubations were stopped by addition of 1.5 vol acetone, and 500 ng PGB₂ was added as internal standard. Samples were extracted as described previously (33). Analysis was carried out using a Waters 5 μ Bondapak C18 RP-HPLC-column (30 cm, 3.9 mm i.d.). Samples dissolved in methanol-water 50:50 (by vol) were injected. As solvent a 45-min gradient, curve 6 on a Waters 660 solvent programmer, from 50:50:0.01 to 80:20:0.01 (by vol) methanol-water-acetic acid, pH adjusted to 5.7 with ammonia, was used at 1.4 ml/min. The eluate was monitored at 280 nm with a Waters 490 UV-detector, and the chromatogram was recorded on a Frensius BD9 recorder. LTB₄, 20-OH-LTB₄, and 20-COOH-LTB₄ were identified by comparison with retention times of synthetic standards (Paesel, Frankfurt, FRG). The peaks were measured manually and quantified by peak area comparison with the internal standard, assuming identical absorbance at 280 nm for all compounds quantified.

Gas chromatography-mass spectrometry. HPLC-eluates believed to contain 20-OH-LTB₅ or 20-COOH-LTB₅ were collected, pooled, acidified to pH 3.5 with H₃PO₄, followed by extraction (34, 35). Gas chromatography-mass spectrometry was performed as described previously (13). Briefly, a Finnigan MAT44s equipped with a DB 1 fused silica capillary column (30 m, 0.25 mm internal diameter, J + W Scientific, Inc., distributed by ICT, Frankfurt, FRG) was used. A portion of 20-OH-LTB₅ was hydrogenated in methanol using PtO₂ as catalyst. All samples were esterified in methanol with ethereal diazomethane. Trimethylsilylethers were generated with BSTFA (1 h, 20°C) (13).

Experiments with endogenous EPA

Volunteer study. Six healthy male volunteers, as judged by a routine clinical examination and normal laboratory screening tests, gave informed consent, and supplemented their otherwise unaltered Western diet with 50 ml of cod liver oil (Peter Möller, Oslo, Norway), containing 11.3% 16:0, 22.8% 18:1, 9.4% EPA, 0.9% 22:5n-3, and 13.8% docosahexaenoic acid (36), per day for 7 days. Volunteers were questioned for side effects. Two hundred ml blood was taken, before and after the dietary intervention, as described. Routine laboratory tests were repeated, and neutrophils were prepared as described above.

Ex vivo studies. Neutrophils were stimulated with 10 μ M ionophore A 23187 for 0, 10, 20, 40, 60, 80, 100, and 120 min. Samples were extracted and analyzed as described above; 3×10^7 unstimulated neutrophils were extracted (37) and subjected to fatty acid analysis as described previously (13).

The study was approved by the Ethics Committee of the faculty of Medicine of the Ludwig-Maximilians Universität, Munich.

Student's two-tailed paired *t*-test was used.

RESULTS

Experiments with exogenous EPA

In vitro studies. When 15 μ M EPA was incubated with human neutrophils, LTB₅ was formed (Fig. 1). A new peak was observed on HPLC, eluting prior to 20-OH-LTB₄, representing a compound more polar than LTB₅. An even more polar peak was noted prior to 20-COOH-LTB₄. Retention times in min (\pm SD), *n* = 10, were: 20-COOH-LTB₄, 10.5 (\pm 0.4); 20-OH-LTB₄, 14.8 (\pm 0.4); PGB₂, 25.1 (\pm 0.4); LTB₅, 26.9 (\pm 0.5); LTB₄, 31.8 (\pm 0.4). In control incubations, without ionophore or in the absence of cells, only the internal standard was detected at 280 nm.

Gas chromatography-mass spectrometry. The less polar peak, with a retention time (\pm SD) of 12.3 (\pm 0.5) min was characterized by gas chromatography-mass spectrometry as 20-OH-LTB₅. The mass spectrum demonstrated interfering fragments from biological background not separated by gas-liquid chromatography. As a methylester-trimethylsilylether derivative 20-OH-LTB₅ displayed the following prominent ions: *m/z* 580 = (M)⁺, the characteristic molecular ion of the derivative of 20-OH-LTB₅, *m/z* 490 = (M-90(Me₃SiOH))⁺ had two mass units less than *m/z* 492, detected from 20-OH-LTB₄ (20, 23), consistent with the additional double bond at C17. (M-(197+90) (-CH₂-CH=CH-CH₂-CH=CH-CH₂-CH₂-OSi(CH₃)₃)⁺ at *m/z* 293 was an ion also obtained from LTB₄, 20-OH-LTB₄, 20-COOH-LTB₄ and LTB₅ (1, 20, 24). When 20-OH-LTB₅ was hydrogenated, and the methylester-trimethylsilylether derivative was injected, prominent ions




Fig. 1. Human polymorphonuclear neutrophils (3×10^7) were stimulated with the ionophore A23187 ($10 \mu\text{M}$, 80 min), in the absence (left), and in the presence of $15 \mu\text{M}$ eicosapentaenoic acid (middle), and after addition of 50 ml/day cod liver oil to an otherwise unchanged diet for 7 days (approximately 5 g eicosapentaenoic acid/day, right). The reaction was terminated by extraction and products were analyzed with a gradient system on RP-HPLC (Methods). Therefore, the baseline is ascending. Absorbance was monitored at 280 nm.

were $m/z 575 = (M-15(\text{CH}_3))^+$ and $m/z 203 = (M-(\text{C}_6-\text{C}_{20}))^+$. They were identical to those detected from hydrogenated 20-OH-LTB₄ (24) after the same derivatization procedure.

The other new peak on HPLC, now identified as 20-COOH-LTB₅, eluted with a shorter retention time (\pm SD) or $5.8 (\pm 0.4)$ min, and was therefore more polar. The mass spectrum obtained from this peak also contained interfering biological background material (**Fig. 2**). Prominent ions detected were: $m/z 446 = (M-90 (\text{Me}_3\text{SiOH}))^+$, two mass units less than the corresponding

fragment $m/z 448$ of 20-COOH-LTB₄ (20, 23), consistent with the additional double bond at C17. Fragments $m/z 415 = (M-(90+31) (\text{OCH}_3))^+$, $m/z 383 = (M-153 (\cdot\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2=\text{CH}-\text{CH}_2-\text{COOCH}_3))^+$, and $m/z 293 = (M-(153+90))^+$ were identical to fragments from LTB₄, 20-OH-LTB₄, 20-COOH-LTB₄, and LTB₅ (1, 20, 24). Fragment ($m/z 255 = (M-281(\text{CH}_3\text{OOC}-(\text{CH}_2)_3-\text{CHOSi}(\text{CH}_3)_3-(\text{CH})_6\cdot))^+$ had two mass units less than the corresponding ion $m/z 257$ of 20-COOH-LTB₄ (20, 24), consistent with the additional double bond at C17.




Fig. 2. Mass spectrum of the methylester-trimethylsilylether derivative of 20-carboxy-leukotriene B₅.




Fig. 3. Human neutrophils were stimulated with ionophore ($10 \mu\text{M}$) for 20–120 min in the presence of $15 \mu\text{M}$ EPA. Depicted is the mean amount of product formed (\pm SEM) in four sets of experiments with blood from different donors.

Time course *in vitro*. Fig. 3 depicts the results of neutrophil stimulations for 20–120 min in the presence of $15 \mu\text{M}$ EPA. Maximum amounts of LTB₅ can be detected at 60 min, when levels of LTB₄ decrease to a nadir. Large and equivalent amounts of 20-OH-LTB₅ and 20-OH-LTB₄ were detectable at 20 min, with 20-OH-LTB₅ remaining quantitatively unaltered, whereas 20-OH-LTB₄ decreased with time. Amounts of 20-COOH-LTB₅ increased more slowly than quantities of 20-COOH-LTB₄.

Concentration curve *in vitro*. In Fig. 4, results of neutrophil stimulation for 80 min in the presence of 0–60 μM EPA are shown. Dose-dependently, addition of EPA increased formation of LTB₅ from undetectable levels in controls and at $0.6 \mu\text{M}$ EPA to $350 \text{ ng}/3 \times 10^7$ cells. Interestingly, levels of LTB₄ increased moderately up to $6 \mu\text{M}$ exogenous EPA, whereas at $15 \mu\text{M}$, LTB₄ started to decline. 20-OH-LTB₅ was detectable in small amounts in control incubations, and increased up to $15 \mu\text{M}$ EPA, and declined at 30 and $60 \mu\text{M}$. Levels of 20-OH-LTB₄ were depressed depending on the dose of exogenous EPA. 20-COOH-LTB₅ was undetectable in controls and at $0.6 \mu\text{M}$ exogenous EPA, then increased up to $15 \mu\text{M}$, and declined to low levels at 30 and $60 \mu\text{M}$. 20-COOH-LTB₄ increased paralleled 20-OH-LTB₄.

Effect of endogenous EPA

Dietary intervention. The addition of 50 ml/day of cod liver oil to an otherwise unaltered diet was well tolerated. No side effects, except “fishy hiccups,” were reported. A detailed routine laboratory check showed no alterations, except a decrease of triacylglycerols (\pm SD) from 131.17 ± 65 to $77.17 \pm 24.3 \text{ mg/dl}$ ($2P < 0.05$), which is consistent with previous reports (14). EPA, 22:5n-3, and docosahexaenoic acid increased in neutrophil phospholipid fatty acids at the expense of linoleic and arachidonic acids (Table 1). Interestingly, 16:0, which is contained in cod liver oil at 11.3%, increased, whereas 18:0 decreased in equivalent amounts.

Ex vivo studies. Whereas LTB₅ and 20-COOH-LTB₅ were not observed prior to dietary intervention, 20-OH-LTB₅ was detectable in small amounts, comparable to small amounts of EPA in neutrophil phospholipid fatty acids. 20-OH-LTB₅ increased, and LTB₅ and 20-COOH-LTB₅ became visible upon addition of EPA to the volunteers’ diet. A representative HPLC tracing, demonstrating 20-OH-LTB₅ and 20-COOH-LTB₅ *ex vivo*, is shown in Fig. 1, right.




Fig. 4. Human neutrophils were stimulated with ionophore for 80 min in the presence of 0–60 μM eicosapentaenoic acid. Depicted is the mean amount of product formed (\pm SEM) in four sets of experiments with blood from different donors.

TABLE 1. Neutrophil phospholipid fatty acid composition before and after 7 days of 50 ml/day cod liver oil, containing 9.4% eicosapentaenoic acid (C20:5n-3) and 13.8% docosahexaenoic acid (C22:6n-3), in healthy human volunteers

Fatty Acid	Control	Cod Liver Oil	P Value
16:0	20.6 (\pm 1.4)	22.6 (\pm 0.5)	0.032
18:0	17.3 (\pm 0.7)	15.0 (\pm 1.5)	0.028
18:1n-9	27.1 (\pm 1.8)	24.7 (\pm 1.7)	0.557
18:2n-6	10.3 (\pm 1.8)	7.6 (\pm 1.1)	0.0001
20:4n-6	14.9 (\pm 1.8)	12.3 (\pm 1.0)	0.006
20:5n-3	0.9 (\pm 0.4)	3.3 (\pm 0.4)	0.0001
22:5n-3	2.0 (\pm 0.5)	3.4 (\pm 0.5)	0.0001
22:6n-3	1.3 (\pm 0.5)	2.6 (\pm 0.4)	0.0001

Values are relative % mean (\pm SD), n = 6, of total fatty acids set as 100%. Student's two-tailed paired *t*-test was applied. Remaining fatty acids were not significantly altered.

The time course of ex vivo formation of LTB₄, 20-OH-LTB₄, 20-COOH-LTB₄ and LTB₅, 20-OH-LTB₅, and 20-COOH-LTB₅ before (left) and after (right) the dietary intervention is depicted in Fig. 5. LTB₄ rapidly decreased from its 10 min value to a nadir at 40 min, followed by a small increase at 60 min, and a slow decrease to the 120 min value. 20-OH-LTB₄ remained in the vicinity of 440 ng/3 \times 10⁷ neutrophils throughout the incubation period. From 10 to 60 min 20-COOH-LTB₄ increased time-dependently from 157 to a plateau around 350 ng/3 \times 10⁷ cells. The kinetics of 20-COOH-LTB₄ remained unaltered by the addition of cod liver oil to the volunteers' diet. Levels of LTB₅ were maximal with 33 ng at 10 min and decreased slowly to 17 ng/3 \times 10⁷ cells. Before dietary cod liver oil, 20-OH-LTB₅ was in the vicinity of 40 ng/3 \times 10⁷ cells; it increased about twofold after the addition of cod liver oil to the diet. 20-COOH-LTB₅ increased slowly from 16 to 42 ng/3 \times 10⁷ cells.

DISCUSSION

We studied human catabolism of LTB₅, a compound that is formed by stimulated neutrophils after enrichment of the diet with EPA (1-3). For the first time, we present definite evidence for formation of 20-OH-LTB₅ and 20-COOH-LTB₅ in vitro and ex vivo.

Proofs of structures of 20-OH-LTB₅ and 20-COOH-LTB₅ were based on four independent lines of evidence. *i*) 20-OH-LTB₅ and 20-COOH-LTB₅ absorb UV light at 280 nm, as does LTB₅, indicating that the intrinsic triene structure remained intact. *ii*) Our HPLC system separated compounds according to polarity and their number of double bonds. More polar compounds eluted first, as evidenced by retention of 20-COOH-LTB₄ < 20-OH-LTB₄ < LTB₄. This was paralleled by retention of 20-COOH-LTB₅ < 20-OH-LTB₅ < LTB₅ (Fig. 1). More-

over, retention times of these EPA derivatives were consistently shorter than those of the respective arachidonic acid derivatives. Interestingly, 20-OH-LTB₅ and 20-COOH-LTB₅ appeared at retention times as anticipated in comparison with retention times of LTB₄, LTB₅, and 20-OH-LTB₄ or LTB₄, LTB₅, and 20-COOH-LTB₄, respectively. *iii*) Human neutrophils possess enzyme systems necessary for the metabolic conversion: neutrophils 20-hydroxylate LTB₄ (20, 24), 12-hydroxy-eicosatetraenoic acid (38), 12-hydroxy-EPA (13), and a number of mono- and di-hydroxyeicosapolyenoic acids (26). LTB₅ seems to competitively inhibit 20-hydroxylation of LTB₄ in a neutrophil enzyme preparation (26). Neutrophils also have been shown to 20-carboxylate 20-OH-LTB₄ (20, 24), and 12,20-dihydroxyeicosatetraenoic acid (33). The metabolic conversions mentioned have largely been found to be catalyzed by cytochrome P-450 enzyme system(s) (22, 23, 25-28). Therefore, in the formation of 20-OH-LTB₅ and 20-COOH-LTB₅, cyto-




Fig. 5. Formation of leukotrienes B during stimulation for 10-120 min in human neutrophils from six volunteers (mean \pm SEM). Neutrophils were prepared from the same volunteers before (left) and after (right) ingestion of 50 ml/day cod liver oil for 7 days in addition to a regular diet. 20-COOH-LTB₅ and LTB₅ were not detectable before cod liver oil ingestion. 20-OH-LTB₅ was significantly elevated after cod liver oil, *P* < or < < 0.05, two-tailed paired *t*-test.

chrome P-450 enzyme system(s) may also be involved. *iv*) Final evidence is derived from the fragmentation pattern of a mass spectrum obtained by gas chromatography-mass spectrometry of 20-COOH-LTB₅ purified by HPLC and derivatized as methylester trimethylsilylether (Fig. 2). Due to interfering biologic background material, not resolvable by gas chromatography, characteristic fragments, but no mass spectrum, of 20-OH-LTB₅ were obtained. In conjunction with the mass spectrum of its derivative 20-COOH-LTB₅, we consider the structure of 20-OH-LTB₅ established.

A 20-hydroxylated metabolite of the EPA-derivative PGE₃ cannot be detected in urine after supplementation of the human diet with fish oil (39, 40). In the same samples, however, PGE₃ and the arachidonic acid derivative PGE₂, as well as its 20-hydroxylated catabolite, can be detected (39, 40). Thus, 20-hydroxylation does not appear to be a universal form of catabolism in the human eicosanoid system.

20-OH-LTB₄ is catabolized to 20-COOH-LTB₄ via the aldehyde intermediate 20-CHO-LTB₄ (29). We did not detect an aldehyde intermediate that can be postulated for conversion of 20-OH-LTB₅ to 20-COOH-LTB₅. When investigating neutrophil 20-carboxylation of 12,20-dihydroxyeicosatetraenoic acid to 12S-hydroxyeicosatetraen-1,20-dioic acid, no evidence for an aldehyde intermediate was obtained (33). The assumed aldehyde intermediate, 20-CHO-LTB₅, may undergo rapid conversion to 20-COOH-LTB₅.

We did not attempt to investigate the enzyme systems involved in great detail. However, some alterations in metabolism of LTB₄ are interesting to note. Exogenous EPA (15 μM) "shifted" levels of LTB₄, lowered levels of 20-OH-LTB₄, and slowed formation of 20-COOH-LTB₄, as compared to control (Fig. 3 and Fig. 5 left). Exogenous EPA (0.6–6 μM) increased levels of LTB₄ at 80 min, whereas levels of 20-OH-LTB₄ decreased (Fig. 4). These findings are in accord with delayed catabolism of LTB₄ being caused by competition for neutrophil 20-hydroxylase (26), as an explanation for increased levels of LTB₄ in the presence of exogenous EPA *in vitro*. The sum of 20-OH-LTB₄ and 20-OH-LTB₅ remained in the vicinity of 500 ng/3 × 10⁷ cells at all time points *in vitro* and *ex vivo* (Figs. 3, 5), and at 0–15 μM exogenous EPA (Fig. 4). *Ex vivo*, levels of LTB₄ were not increased by the administration of n-3 fatty acids. Thus, *ex vivo*, neutrophil 20-hydroxylase seems to have a limited, but sufficient, capacity to inactivate the amounts formed of both LTB₄ and LTB₅. Competition for 20-carboxylation between 20-OH-LTB₄ and 20-OH-LTB₅ is also likely to occur, and merits further study.

20-OH-LTB₅ and 20-COOH-LTB₅ possess the same rigid structure in the C17–C18 region of the molecule as does LTB₅. This rigidity, due to the n-3 double bond, has been thought to interfere with the active site specificity of

LTB₅ to a substantial degree (41). Moreover, LTB₄ is sequentially inactivated by transformation to its 20-OH and 20-COOH derivatives (20, 24). LTB₅, which has little proinflammatory activity (8, 9), might very well be inactivated further along the same route. Although biological properties not as yet characterized may be attributable to LTB₅, we speculate that 20-OH-LTB₅ and 20-COOH-LTB₅ may not be biologically active.

Assuming that catabolism of leukotrienes B occurred after formation, and formation was completed within a limited time, we used a 2-h time-frame for neutrophil stimulations. Unexpectedly, both leukotrienes B and all their respective catabolites were detectable in considerable amounts at all timepoints studied. Therefore, rather than peak levels, overall amounts of leukotrienes B formed may be of biologic significance.

Neutrophil phospholipid fatty acid composition was altered dramatically by the dietary intervention. EPA increased fourfold, and docosahexaenoic acid doubled in the neutrophil membrane. Importantly, incorporation of n-3 fatty acids occurred at the sole expense of n-6 fatty acids (Table 1). 22:5n-3 is present only in trace amounts in the cod liver oil used. 22:5n-3 increased in phospholipid neutrophil fatty acids. Presumably 22:5n-3 is derived from EPA by endogenous chain-elongation (42); its biological properties however, remain to be elucidated in humans (43, 44).

Our 1 week supplementation of cod liver oil reduced the amount of arachidonic acid in neutrophil membranes to the same degree as was observed in much longer dietary intervention studies (14). In our study, the amount




Fig. 6. Catabolism of leukotriene B₅ in human polymorphonuclear neutrophils.

LTB₄ formed ex vivo was unaltered (Fig. 5). In 4–6 week studies, formation of LTB₄ was reduced under comparable assay conditions (2, 3, 14, 16–19). In vitro, inhibition of LTB₄ formation can only be induced by large amounts of exogenous EPA leading to ratios of LTB₄ to LTB₅ not attained ex vivo (Figs. 4 and 5, refs. 1, 2, 11, 12). Labeled human neutrophils (2) or platelets (32) release a lower percentage of radioactive arachidonic acid upon stimulation during long-term dietary n-3 fatty acids than in control periods. Thus, reduced production of LTB₄ by human neutrophils during long-term ingestion of n-3 fatty acids cannot simply be explained by reduced arachidonic acid content or competition for 5-lipoxygenase.

We investigated human neutrophil catabolism of LTB₅, as it occurs in vitro, and ex vivo after a diet rich in EPA. LTB₅ is catabolized to 20-OH-LTB₅, which in turn is metabolized to 20-COOH-LTB₅ (Fig. 6). Presumably the same enzyme systems are involved in the catabolism of LTB₅ that are responsible for catabolism of LTB₄. Although we present evidence for competition of LTB₄ and LTB₅ for catabolism to their respective 20-OH-derivatives, and of these to their respective 20-COOH-derivatives in vitro, ex vivo catabolism of proinflammatory LTB₄ was not impeded. ■

This work was supported by the Deutsche Forschungsgemeinschaft (Scha 398). We thank Rosemarie Kiefl for expert technical assistance.

Manuscript received 2 February 1990 and in revised form 12 June 1990.

REFERENCES

- Strasser, T., S. Fischer, and P. C. Weber. 1985. Leukotriene B₅ is formed in human neutrophils after dietary supplementation with icosapentaenoic acid. *Proc. Natl. Acad. Sci. USA.* **82**: 1540–1543.
- Lee, T. H., R. L. Hoover, J. D. Williams, R. I. Sperling, J. Ravalese, B. W. Spur, D. W. Robinson, E. J. Corey, R. A. Lewis, and K. F. Austen. 1985. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acid on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. *N. Engl. J. Med.* **312**: 1217–1224.
- Prescott, S. M., G. A. Zimmerman, and A. R. Morrison. 1985. The effects of a diet rich in fish oil on human neutrophils: identification of LTB₅ as a metabolite. *Prostaglandins.* **30**: 209–227.
- Borgeat, P., and B. Samuelsson. 1979. Arachidonic acid metabolism in polymorphonuclear leukocytes: effect of ionophore A23187. *Proc. Natl. Acad. Sci. USA.* **76**: 2148–2152.
- Goetzl, E. J., and W. C. Pickett. 1980. The human PMN leukocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETEs). *J. Immunol.* **125**: 1789–1791.
- Ford-Hutchinson, A. W., M. A. Bray, M. V. Doig, M. E. Shipley, and M. J. H. Smith. 1980. Leukotriene B₄, a potent chemokinetic and aggregating substance released from polymorphonuclear neutrophils. *Nature (London)* **286**: 264–265.
- Palmblad, J., C. L. Malmsten, A. M. Udén, O. Rådmark, L. Engstedt, and B. Samuelsson. 1981. Leukotriene B₄ is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence. *Blood.* **58**: 658–661.
- Goldman, D. W., W. C. Pickett, and E. J. Goetzl. 1983. Human neutrophil chemotactic and degranulating activities of leukotriene B₅ (LTB₅) derived from eicosapentaenoic acid. *Biochem. Biophys. Res. Commun.* **117**: 282–288.
- Lee, T. H., J. M. Mencia-Huerta, C. Shih, E. J. Corey, R. A. Lewis, and K. F. Austen. 1984. Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B₅ and the double lipoxygenase product. *J. Biol. Chem.* **259**: 2383–2389.
- Charleson, S., J. F. Evans, R. J. Zamboni, Y. Leblanc, B. J. Fitzsimmons, C. Leveille, P. Dupuis, and A. Ford-Hutchinson. 1986. Leukotriene B₃, leukotriene B₄, and leukotriene B₅: binding to leukotriene B₄ receptors on rat and human leukocyte membranes. *Prostaglandins.* **32**: 503–516.
- Lee, T. H., J. M. Mencia-Huerta, S. Shih, E. J. Corey, R. A. Lewis, and K. F. Austen. 1984. Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. *J. Clin. Invest.* **74**: 1922–1933.
- Prescott, S. M. 1984. The effect of eicosapentaenoic acid on leukotriene B production by human neutrophils. *J. Biol. Chem.* **259**: 7615–7621.
- von Schacky, C., A. J. Marcus, L. B. Safier, H. L. Ullman, N. Islam, M. J. Broekman, and S. Fischer. 1990. Platelet-neutrophil interactions. 12S,20- and 5S,12S-dihydroxyeicosapentaenoic acids: two novel neutrophil metabolites from platelet-derived 12S-hydroxyeicosapentaenoic acid. *J. Lipid Res.* **31**: 801–810.
- von Schacky, C. 1987. Prophylaxis of atherosclerosis with marine omega-3 fatty acids—a comprehensive strategy. *Ann. Int. Med.* **107**: 890–899.
- Endres, S., R. Ghorbani, V. E. Kelley, K. Georgilis, G. Lonneman, J. W. M. van der Meer, J. G. Cannon, T. S. Rogers, M. S. Klempner, P. C. Weber, E. J. Schaefer, S. M. Wolff, and C. A. Dinarello. 1989. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by monoclear cells. *N. Engl. J. Med.* **320**: 265–271.
- Payan, D. G., M. Y. S. Wong, T. Chernov-Rogan, F. H. Valone, W. C. Pickett, V. A. Blake, W. M. Gold, and E. J. Goetzl. 1986. Alterations in human leukocyte function by ingestion of eicosapentaenoic acid. *J. Clin. Immun.* **6**: 402–410.
- Sperling, R. I., M. Weinblatt, J.-L. Robin, J. Ravalese, R. L. Hoover, F. House, J. S. Coblyn, P. A. Fraser, B. W. Spur, D. W. Robinson, R. A. Lewis, and K. F. Austen. 1987. Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. *Arthritis Rheum.* **30**: 988–997.
- Arm, J. P., C. C. Horton, J. M. Mencia-Huerta, F. House, N. M. Eiser, T. J. H. Clark, B. W. Spur, and T. H. Lee. 1988. Effect of dietary supplementation with fish oil lipids on mild asthma. *Thorax.* **43**: 84–92.
- Lorenz, R., P. C. Weber, P. Szimnau, H. Heldwein, T. Strasser, and K. Loeschke. 1989. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease—a randomised, placebo-controlled, double-blind cross-over trial. *J. Int. Med.* **225**, Suppl. 1: 225–232.
- Hansson, G., J. Å. Lindgren, S.-E. Dahlén, P. Hedquist, and B. Samuelsson. 1981. Identification and biological ac-

- tivity of novel ω -oxidized metabolites of leukotriene B₄ from human leukocytes. *FEBS Lett.* **130**: 107-112.
21. Jubiz, W., O. Rådmark, C. Malmsten, G. Hansson, J. Å. Lindgren, J. Palmblad, A-M. Udén, and B. Samuelsson. 1982. A novel leukotriene produced by stimulation of leukocytes with formylmethionylleucyl-phenylalanine. *J. Biol. Chem.* **257**: 6106-6110.
 22. Shak, S., and I. M. Goldstein. 1984. Carbon monoxide inhibits ω -oxidation of leukotriene B₄ by human polymorphonuclear leukocytes: evidence that catabolism of leukotriene B₄ is mediated by a cytochrome P-450 enzyme. *Biochem. Biophys. Res. Commun.* **123**: 475-481.
 23. Powell, W. S. 1984. Properties of leukotriene B₄ 20-hydroxylase from polymorphonuclear leukocytes. *J. Biol. Chem.* **259**: 3082-3089.
 24. Shak, S., and I. M. Goldstein. 1984. ω -Oxydation is the major pathway for the catabolism of leukotriene B₄ in human polymorphonuclear leukocytes. *J. Biol. Chem.* **259**: 10181-10187.
 25. Shak, S., and I. M. Goldstein. 1985. Leukotriene B₄ ω -hydroxylase in human polymorphonuclear leukocytes. Partial purification and identification as a cytochrome P-450. *J. Clin. Invest.* **76**: 1218-1228.
 26. Soberman, R. J., R. T. Okita, B. Fitzsimmons, J. Rokach, B. Spur, and K. F. Austen. 1987. Stereochemical requirements for substrate specificity of LTB₄ 20-hydroxylase. *J. Biol. Chem.* **262**: 12421-12427.
 27. Hatzelmann, A., and V. Ullrich. 1985. The ω -hydroxylation of arachidonic acid by human polymorphonuclear leukocytes. *Eur. J. Biochem.* **173**: 445-452.
 28. Marcus, A. J., L. B. Safier, H. L. Ullman, N. Islam, M. J. Broekman, and C. von Schacky. 1987. Studies on the mechanism of ω -hydroxylation of platelet 12-hydroxyeicosatetraenoic acid (12-HETE) by unstimulated neutrophils. *J. Clin. Invest.* **79**: 179-187.
 29. Soberman, R. J., J. P. Sutyak, R. T. Okita, D. E. Wendelborn, L. J. Roberts, and K. F. Austen. 1988. The identification and formation of 20-aldehyde leukotriene B₄. *J. Biol. Chem.* **263**: 7996-8002.
 30. Mahadevappa, V. G., and W. S. Powell. 1989. The metabolism of arachidonic and eicosa-pentaenoic acids in human neutrophils stimulated by A23187 and FMLP. *J. Cell. Biochem.* **40**: 341-352.
 31. Ahmed, A. A., and B. J. Holub. 1984. Alteration and recovery of bleeding times, platelet aggregation and fatty acid composition of individual phospholipids in platelets of human subjects receiving a supplement of cod liver oil. *Lipids.* **19**: 617-624.
 32. von Schacky, C., W. Siess, S. Fischer, and P. C. Weber. 1985. A comparative study of eicosapentaenoic acid metabolism by human platelets in vivo and in vitro. *J. Lipid Res.* **26**: 457-464.
 33. Marcus, A. J., L. B. Safier, H. L. Ullman, N. Islam, M. J. Broekman, J. R. Falck, S. Fischer, and C. von Schacky. 1988. Platelet-neutrophil interactions. 12S-Hydroxyeicosatetraen-1,20-dioic acid: a new eicosanoid synthesized by unstimulated neutrophils from 12S,20-dihydroxyeicosatetraenoic acid. *J. Biol. Chem.* **263**: 2223-2229.
 34. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol.* **37**: 911-917.
 35. Shak, S. 1987. Leukotriene B₄ catabolism: quantitation of leukotriene B₄ and its ω -oxidation products by reversed-phase high-performance liquid chromatography. *Methods Enzymol.* **141**: 355-371.
 36. von Schacky, C., S. Fischer, and P. C. Weber. 1985. Long term effects of dietary marine n-3 fatty acids upon plasma- and cellular-lipids, platelet function and eicosanoid formation in humans. *J. Clin. Invest.* **76**: 1626-1631.
 37. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipids from animal tissues. *J. Biol. Chem.* **226**: 497-509.
 38. Marcus, A. J., L. B. Safier, H. L. Ullman, N. Islam, M. J. Broekman, J. R. Falck, S. Fischer and C. von Schacky. 1987. Cell-cell interactions in the eicosanoid pathway. *Ann. N.Y. Acad. Sci.* **516**: 407-411.
 39. Fischer, S., C. von Schacky, and H. Schweer. 1988. Prostaglandins E₃ and F_{3 α} are excreted in human urine after ingestion of n-3 polyunsaturated fatty acids. *Biochim. Biophys. Acta.* **963**: 501-508.
 40. Knapp, H. R., and G. A. FitzGerald. 1989. The antihypertensive effects of fish oil. A controlled study of polyunsaturated fatty acid supplements in essential hypertension. *N. Engl. J. Med.* **320**: 1037-1043.
 41. Lee, T. H., T. Sethi, A. E. G. Crea, W. Peters, J. P. Art, C. E. Horton, M. J. Walport, and B. W. Spur. 1988. Characterization of leukotriene B₃: comparison of its biological activities with leukotriene B₄ and leukotriene B₅ in complement receptor enhancement, lysozyme release and chemotaxis of human neutrophils. *Clin. Sci.* **74**: 467-475.
 42. von Schacky, C., and P. C. Weber. 1985. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. *J. Clin. Invest.* **76**: 2446-2450.
 43. Careaga, M. M., and H. Sprecher. 1984. Synthesis of two hydroxy fatty acids from 7,10,13,16,19-docosapentaenoic acid by human platelets. *J. Biol. Chem.* **259**: 14413-14417.
 44. Ackman, R. G., and C. A. Eaton. 1988. N-3 docosapentaenoic acid in blubber of dam and pup grey seals (*Halichoerus gypus*): implications in the Inuit diet and for human health. *Can. J. Zool.* **66**: 2428-2431.